Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001437749-16-034209
Filing Date
2016-06-22
Accepted
2016-06-22 09:31:10
Documents
2
Period of Report
2016-06-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 rdgdoc.html 4  
1 FORM 4 rdgdoc.xml 4 2905
2 EKIZIAN POA ekizianpoa.htm EX-24 6342
  Complete submission text file 0001437749-16-034209.txt   10886
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Issuer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 7389 Services-Business Services, NEC

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address
Ekizian Gregory (Reporting) CIK: 0001666010 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-51353 | Film No.: 161725728